Royce & Associates LP Lowers Position in Palvella Therapeutics, Inc. $PVLA

Royce & Associates LP trimmed its holdings in shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) by 33.6% during the 3rd quarter, Holdings Channel reports. The fund owned 49,509 shares of the company’s stock after selling 25,007 shares during the period. Royce & Associates LP’s holdings in Palvella Therapeutics were worth $3,104,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in PVLA. Intech Investment Management LLC purchased a new stake in shares of Palvella Therapeutics in the 3rd quarter worth approximately $259,000. Vanguard Group Inc. increased its holdings in Palvella Therapeutics by 202.0% during the third quarter. Vanguard Group Inc. now owns 494,656 shares of the company’s stock valued at $31,010,000 after buying an additional 330,847 shares during the period. JPMorgan Chase & Co. raised its stake in Palvella Therapeutics by 33.7% in the third quarter. JPMorgan Chase & Co. now owns 4,338 shares of the company’s stock worth $272,000 after buying an additional 1,093 shares in the last quarter. Aberdeen Group plc purchased a new stake in Palvella Therapeutics during the third quarter worth $3,212,000. Finally, Alps Advisors Inc. bought a new stake in Palvella Therapeutics during the 3rd quarter valued at $344,000. Hedge funds and other institutional investors own 40.11% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. BTIG Research lifted their price target on Palvella Therapeutics from $192.00 to $215.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Mizuho raised their price objective on Palvella Therapeutics from $205.00 to $250.00 and gave the company an “outperform” rating in a research report on Wednesday, February 25th. UBS Group reiterated a “buy” rating and issued a $143.00 target price on shares of Palvella Therapeutics in a research note on Monday, December 15th. Canaccord Genuity Group boosted their target price on shares of Palvella Therapeutics from $148.00 to $204.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. Finally, Truist Financial set a $210.00 price target on shares of Palvella Therapeutics in a report on Tuesday, February 24th. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $176.44.

Palvella Therapeutics Price Performance

Shares of NASDAQ:PVLA opened at $134.95 on Friday. The business’s 50-day moving average is $96.80 and its 200 day moving average is $82.44. Palvella Therapeutics, Inc. has a 1 year low of $18.23 and a 1 year high of $151.18. The firm has a market capitalization of $1.60 billion, a P/E ratio of -51.31 and a beta of -0.30.

Insider Activity

In related news, Director George M. Jenkins bought 4,000 shares of the company’s stock in a transaction on Friday, February 27th. The shares were bought at an average price of $125.00 per share, with a total value of $500,000.00. Following the transaction, the director owned 187,171 shares in the company, valued at approximately $23,396,375. This trade represents a 2.18% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Kathleen Goin sold 4,302 shares of the company’s stock in a transaction that occurred on Wednesday, January 21st. The shares were sold at an average price of $97.63, for a total transaction of $420,004.26. The disclosure for this sale is available in the SEC filing. Corporate insiders own 20.50% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.